Answers are grounded in this paper and cite their sources.
Progestogen hypersensitivity (PH) describes hypersensitivity reactions to endogenous progesterone, classically termed autoimmune progesterone dermatitis, or to exogenous progestogens. Non-cyclical presentations can be difficult to distinguish from other dermatoses. We describe a case of a 46-year-old woman who developed a widespread pruritic rash 52 days after starting oral norethisterone for heavy menstrual bleeding. The rash began on her arms and progressed to involve the trunk and legs, with papules, pustules, confluent erythema, and crusting. Purpuric, targetoid lesions later developed on her lower legs, followed by pompholyx-like vesicles on her palms and a periorbital eczematous rash. Her eosinophil count was 1.2×109/L (normal range: 0.02-0.50x109/L) and C-reactive protein 16 mg/L (normal range: <5 mg/L). She was afebrile, with no mucosal involvement and no evidence of hepatic or renal dysfunction at presentation. Herpes simplex and varicella-zoster PCR were negative. Skin biopsy showed acanthosis, parakeratosis, and spongiosis, with a dermal infiltrate of lymphocytes and eosinophils. The clinical differentials included a drug eruption, pustular folliculitis, atypical pityriasis rubra pilaris, and erythema multiforme. Norethisterone was stopped, and she was treated with potent topical corticosteroids and a six-week tapering course of oral prednisolone, starting at 30 mg daily. Her skin was largely clear about nine weeks after norethisterone was stopped, with no relapse to date. Discussion at the clinicopathological meeting concluded that this was a delayed-type hypersensitivity reaction to norethisterone, consistent with exogenous PH. She declined a progesterone challenge and was advised to avoid progestogen-containing hormone therapy. This case describes a polymorphic, non-cyclical presentation of PH caused by an oral synthetic progestogen. It may complicate future management of menopausal symptoms, as women with an intact uterus usually require a progestogen alongside estrogen therapy to protect the endometrium.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: